spacer
home > > autumn 2008 > commitment issues
PUBLICATIONS


Commitment Issues

As with all regulations, some are easier to follow than others. There are always going to be scenarios ‘at the margins’ where any regulation will struggle to define the correct procedure or process for dealing with a specific issue, or may appear to be in conflict with some other aspect of best practice.

This has been amply illustrated within the laboratory sector in recent times, with the delayed implementation of General Chapter <467> Residual Solvents of the United States Pharmacopoeia – National Formulary (USP-NF). This proposed revision to the USP-NF had first been scheduled for introduction on 1st January 2007, only for implementation to be delayed until 1st July 2007, and then further delayed with an implementation date of 1st July 2008.

BACKGROUND TO CHAPTER <467>

The essential rationale behind USP <467> is an attempt to harmonise test standards for residual solvents for medicines sold in the US in accordance with a model already adopted by the European Pharmacopeia. It aims to prescribe standard test methods for three classes of solvent. These are:

  • Class 1 solvents, a defined list of chemicals that are known or suspected to be human carcinogens
  • Class 2 solvents, a defined list known to be animal carcinogens or to exhibit other toxicity
  • Class 3 solvents, a defined list of chemicals having low toxic potential

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Philip Payne is Business Development Manager for RSSL Pharma. He joined from Italian API producer, Steroid, where he was General Manager with responsibility for sales, procurement, production and analysis. Fluent in Italian, French and English, and with broad experience of research and production, Philip now assists RSSL Pharma in promoting its analytical and training services more widely across Europe, in addition to the UK and Ireland.
spacer
Philip Payne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement